SAS Output

26-APR-2018 6:10

GU ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1500-pRCC,Adv, Sunitinib vs MET inhib 1 Y 1 Sunitinib 180 20 11 6 2 1 0 07/25/2016 225 96
        2 Cabozantinib   18 10 6 3 0 0      
        3 Crizotinib   21 13 8 4 2 2      
        4 Savolitinib   20 11 7 3 1 1      
            79 45 27 12 4 3      
 
  S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 969 32 29 17 9 3 0 02/24/2017 148 63
        2 Tokyo-172 BCG   31 29 17 10 5 1      
        3 Prime + Tokyo-172 BCG   29 28 15 8 3 0      
            92 86 49 27 11 1      
 
  S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab 1 Y 1 Atezolizumab 148 41 39 25 10 2 1 03/13/2017 159 71
            41 39 25 10 2 1      
 
Yes A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 1 E Total Registrations   3 1 1 1 0 0 11/23/2016 60 33
            3 1 1 1 0 0      
 
  EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) 0 E Total Registrations   15 15 12 8 3 1 09/29/2017   38
            15 15 12 8 3 1      
 
    1 E Total Registrations   11 11 8 5 1 0 09/29/2017    
            11 11 8 5 1 0      
 
  NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel 1 E Total Registrations   1 1 0 0 0 0 08/24/2017   123
            1 1 0 0 0 0      
 
    2 E Total Registrations   1 1 0 0 0 0 08/24/2017    
            1 1 0 0 0 0      
 
No R0924-Pros, NADT+WPRT vs. NADT+P&SV RT 1 E Total Registrations   72 30 16 8 0 0 11/25/2013   176
            72 30 16 8 0 0